glp 1 agonist australia An update on GLP-1 agonists: where do they fit in the type 2 diabetes management algorithm? GLP-1 Receptor Agonist Market Size
Description
Studies show that weight loss can lower total cholesterol levels in the body
Rising Global Prevalence of Type 2 Diabetes and Obesity The rising global prevalence of type 2 diabetes and obesity is boosting the need for the GLP-1 receptor agonist, as these conditions represent the primary therapeutic targets for this drug class
By harnessing the complementary biology of two endogenous hormones, these agents achieve metabolic effects on glycemia, body weight, lipid handling, and cardiovascular risk that neither hormone can fully replicate alone
These findings help answer whether GLP-1 is safe for long-term use
